IFM Investors Pty Ltd Purchases 956 Shares of Axon Enterprise, Inc $AXON

Posted by ABMN Staff on Jul 3rd, 2026

IFM Investors Pty Ltd boosted its position in Axon Enterprise, Inc (NASDAQ:AXON – Free Report) by 6.3% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 16,042 shares of the biotechnology company’s stock after buying an additional 956 shares during the quarter. IFM Investors Pty Ltd’s holdings in Axon Enterprise were worth $6,813,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in the company. Mayflower Financial Advisors LLC increased its holdings in Axon Enterprise by 12.5% in the 1st quarter. Mayflower Financial Advisors LLC now owns 603 shares of the biotechnology company’s stock worth $256,000 after acquiring an additional 67 shares during the last quarter. Lansforsakringar Fondforvaltning AB publ boosted its position in Axon Enterprise by 5.5% during the first quarter. Lansforsakringar Fondforvaltning AB publ now owns 24,263 shares of the biotechnology company’s stock worth $10,304,000 after purchasing an additional 1,264 shares during the period. Apollon Wealth Management LLC boosted its position in Axon Enterprise by 13.1% during the first quarter. Apollon Wealth Management LLC now owns 4,666 shares of the biotechnology company’s stock worth $1,982,000 after purchasing an additional 539 shares during the period. Cornerstone Wealth Group LLC bought a new position in Axon Enterprise during the first quarter worth about $280,000. Finally, Union Bancaire Privee UBP SA increased its stake in shares of Axon Enterprise by 4.3% in the first quarter. Union Bancaire Privee UBP SA now owns 1,457 shares of the biotechnology company’s stock worth $619,000 after purchasing an additional 60 shares in the last quarter. 79.08% of the stock is currently owned by institutional investors.

Axon Enterprise Stock Up 0.5%

AXON stock opened at $597.04 on Friday. The stock has a 50-day simple moving average of $433.80 and a two-hundred day simple moving average of $481.59. Axon Enterprise, Inc has a twelve month low of $339.01 and a twelve month high of $885.91. The firm has a market capitalization of $48.12 billion, a PE ratio of 239.78, a PEG ratio of 12.12 and a beta of 1.38. The company has a quick ratio of 1.93, a current ratio of 2.27 and a debt-to-equity ratio of 0.49.

Axon Enterprise (NASDAQ:AXON – Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.01. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. The firm had revenue of $807.35 million for the quarter, compared to the consensus estimate of $778.90 million. During the same period in the prior year, the firm posted $1.47 earnings per share. The company’s revenue for the quarter was up 33.7% on a year-over-year basis. On average, equities analysts predict that Axon Enterprise, Inc will post 1.63 EPS for the current fiscal year.

Insider Buying and Selling at Axon Enterprise

In other Axon Enterprise news, CRO Cameron Brooks sold 1,242 shares of the firm’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $500.00, for a total value of $621,000.00. Following the completion of the transaction, the executive directly owned 49,710 shares of the company’s stock, valued at $24,855,000. This trade represents a 2.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Caitlin Elizabeth Kalinowski sold 564 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $478.97, for a total transaction of $270,139.08. Following the transaction, the director owned 3,632 shares of the company’s stock, valued at $1,739,619.04. This trade represents a 13.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 48,989 shares of company stock worth $24,090,083 in the last ninety days. Insiders own 4.20% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on AXON shares. Citizens Jmp reissued a “market outperform” rating and issued a $700.00 price target on shares of Axon Enterprise in a research report on Thursday, June 25th. Barclays cut their price objective on shares of Axon Enterprise from $682.00 to $523.00 and set an “overweight” rating for the company in a report on Friday, May 8th. JPMorgan Chase & Co. lifted their price objective on shares of Axon Enterprise from $750.00 to $755.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Weiss Ratings raised shares of Axon Enterprise from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, May 8th. Finally, Piper Sandler restated an “overweight” rating and set a $674.00 target price on shares of Axon Enterprise in a research report on Monday, June 15th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $712.75.

Get Our Latest Stock Analysis on Axon Enterprise

More Axon Enterprise News

Here are the key news stories impacting Axon Enterprise this week:

Positive Sentiment: Axon continues to show strong fundamental momentum, with recent quarterly revenue up 33.7% year over year and earnings topping estimates. Management has also signaled confidence in growth from software, digital evidence, and Dedrone, which supports the bull case. AXON Gains From Strength in Software & Services Unit: Can the Momentum Sustain?
Positive Sentiment: News that Brown Advisory’s Large-Cap Growth Strategy picked up Axon during a broader sell-off adds another signal of institutional interest in the name. Brown Advisory Large-Cap Growth Strategy Picked Axon Enterprises (AXON) Amid Broader Sell-Off
Positive Sentiment: Investor optimism is also being lifted by speculation that Axon could benefit from expanding public-safety and federal demand, including possible future drone-related applications and larger government procurement. Axon’s Next Big Policing Bet Could Be Nonlethal Drones
Neutral Sentiment: Axon’s CEO highlighted the company’s long-term mission to replace guns with technology, reinforcing the growth narrative but offering little immediate financial impact. How Axon is replacing guns with tech
Neutral Sentiment: One recent insider filing showed CEO Patrick Smith sold 10,000 shares under a pre-arranged trading plan; the sale is worth watching but is not necessarily a negative signal by itself. Patrick Smith Sells 10,000 Shares of Axon Enterprise (NASDAQ:AXON) Stock
Negative Sentiment: The Trump/ICE contract controversy has introduced ethics and reputational risk around Axon’s federal business, which could weigh on sentiment if political scrutiny intensifies. Hillary Clinton Escalates Trump Criticism, Cites Reports Linking Stock Purchases to Federal ICE Contract Decisions

About Axon Enterprise

(Free Report)

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.